See more : Hancock & Gore Ltd (HNG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Bicycle Therapeutics plc (BCYC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bicycle Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Klaveness Combination Carriers ASA (KCC.OL) Income Statement Analysis – Financial Results
- Way 2 Vat Ltd (W2V.AX) Income Statement Analysis – Financial Results
- Bolsa Mexicana de Valores, S.A.B. de C.V. (BOMXF) Income Statement Analysis – Financial Results
- Inageya Co., Ltd. (8182.T) Income Statement Analysis – Financial Results
- Hancom Inc. (030520.KQ) Income Statement Analysis – Financial Results
Bicycle Therapeutics plc (BCYC)
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.98M | 14.46M | 11.70M | 10.39M | 13.80M | 7.14M | 2.06M | 0.00 |
| Cost of Revenue | 6.47M | 3.69M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 269.29K |
| Gross Profit | 20.51M | 10.78M | -33.18M | -22.76M | -11.74M | -13.63M | -9.81M | -269.29K |
| Gross Profit Ratio | 76.03% | 74.51% | -283.69% | -219.05% | -85.06% | -190.93% | -476.02% | 0.00% |
| Research & Development | 156.50M | 81.61M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 9.77M |
| General & Administrative | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.78M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -325.11K |
| SG&A | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.45M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -5.38M | -665.00K | -119.00K | 0.00 |
| Operating Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.22M |
| Cost & Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.49M |
| Interest Income | 14.00M | 5.76M | 120.00K | 683.00K | 814.00K | 169.00K | 50.00K | 8.00K |
| Interest Expense | 3.26M | 3.34M | 2.98M | 457.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55M | 3.69M | 1.41M | 1.29M | 963.97K | 710.80K | 335.56K | 269.29K |
| EBITDA | -183.40M | -112.96M | -64.08M | -50.39M | -30.03M | -21.49M | -15.88M | -13.26M |
| EBITDA Ratio | -679.86% | -766.76% | -559.96% | -493.52% | -190.56% | -294.76% | -770.92% | 0.00% |
| Operating Income | -189.95M | -116.65M | -65.62M | -51.96M | -26.30M | -21.75M | -16.21M | -13.49M |
| Operating Income Ratio | -704.13% | -806.56% | -560.98% | -500.10% | -190.56% | -304.74% | -787.04% | 0.00% |
| Total Other Income/Expenses | 10.74M | 2.41M | -2.86M | 226.00K | -4.56M | -496.00K | -69.00K | -37.90K |
| Income Before Tax | -179.21M | -114.24M | -68.48M | -51.73M | -30.86M | -22.24M | -16.28M | -13.53M |
| Income Before Tax Ratio | -664.32% | -789.88% | -585.47% | -497.92% | -223.62% | -311.69% | -790.39% | 0.00% |
| Income Tax Expense | 1.46M | -1.52M | -1.66M | -724.00K | -254.00K | -396.00K | -23.00K | -20.94K |
| Net Income | -180.66M | -112.72M | -66.82M | -51.01M | -30.61M | -21.85M | -16.26M | -13.51M |
| Net Income Ratio | -669.72% | -779.35% | -571.25% | -490.95% | -221.78% | -306.14% | -789.27% | 0.00% |
| EPS | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| EPS Diluted | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| Weighted Avg Shares Out | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
| Weighted Avg Shares Out (Dil) | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength
Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021
Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences
OXURION NV to Present at Wet AMD and DME Drug Development Summit
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
OXURION to Participate in Upcoming Investor Meetings
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports